Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study

Armando Santoro; Rita Mazza; Alessandro Pulsoni; Alessandro Re; Maurizio Bonfichi; Vittorio Ruggero Zilioli; Flavia Salvi; Francesco Merli; Antonella Anastasia; Stefano Luminari; Giorgia Annechini; Manuel Gotti; Annalisa Peli; Anna Marina Liberati; Nicola Di Renzo; Luca Castagna; Laura Giordano; Carmelo Carlo‐Stella

doi:10.1200/jco.2016.66.4466

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

This phase II study demonstrates that BeGEV is an effective salvage regimen able to induce CR in a high proportion of patients with relapsed or refractory HL before ASCT. These data provide a strong rationale for further development of the BeGEV regimen.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Santoro et al. (2016) studied this question.

synapsesocial.com/papers/69d97e215e5bcb4e3b836d5e https://doi.org/10.1200/jco.2016.66.4466

View Full Paper

Ask AI

Bookmark

Share

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study

Ask about this paper

Abstract

Discussion

Cite This Study

Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading